表紙
市場調査レポート

喘息:パイプライン製品の分析

Asthma - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232777
出版日 ページ情報 英文 772 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
喘息:パイプライン製品の分析 Asthma - Pipeline Review, H1 2016
出版日: 2016年04月27日 ページ情報: 英文 772 Pages
概要

喘息は、気道が炎症によって狭くなる慢性疾患です。喘息の症状としては、息切れ、胸苦しさや痛み、慢性的な咳などがあり、その原因としては、喘息にかかりやすい家系、過体重、喫煙、排ガスやその他の大気汚染物質にさらされることなどが挙げられます。喘息の代表的な治療薬としては、吸入コルチコステロイド薬、ロイコトリエン拮抗薬、抗ヒスタミン剤、充血除去剤などがあります。

当レポートでは、喘息治療薬におけるパイプライン製品の概要や治験の段階別の製品概要、主要企業のプロファイル、薬剤のプロファイル、パイプライン製品の最新動向などを提供しています。

イントロダクション

喘息の概要

治療薬の開発

喘息:企業で開発中の治療薬

喘息:大学/機関で研究中の治療薬

喘息:パイプライン製品の概況

喘息:企業で開発中の製品

喘息:大学/機関で研究中の製品

喘息の治療薬開発に従事している企業

喘息:治療薬の評価

薬剤プロファイル

喘息:最近のパイプライン動向

喘息:休止中のプロジェクト

喘息:開発が中止された製品

喘息:製品開発のマイルストーン

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7683IDB

Summary

Global Markets Direct's, 'Asthma - Pipeline Review, H1 2016', provides an overview of the Asthma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Asthma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Asthma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Asthma
  • The report reviews pipeline therapeutics for Asthma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Asthma therapeutics and enlists all their major and minor projects
  • The report assesses Asthma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Asthma

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Asthma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Asthma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Asthma Overview
  • Therapeutics Development
    • Asthma - Therapeutics under Development by Companies
    • Asthma - Therapeutics under Investigation by Universities/Institutes
    • Asthma - Pipeline Products Glance
    • Asthma - Products under Development by Companies
    • Asthma - Products under Investigation by Universities/Institutes
    • Asthma - Companies Involved in Therapeutics Development
    • Asthma - Therapeutics Assessment
  • Drug Profiles
    • Asthma - Recent Pipeline Updates
    • Asthma - Dormant Projects
    • Asthma - Discontinued Products
    • Asthma - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Asthma, H1 2016
  • Number of Products under Development for Asthma - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Development by Companies, H1 2016 (Contd..8)
  • Number of Products under Development by Companies, H1 2016 (Contd..9)
  • Number of Products under Development by Companies, H1 2016 (Contd..10)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Development by Companies, H1 2016 (Contd..12)
  • Products under Development by Companies, H1 2016 (Contd..13)
  • Products under Development by Companies, H1 2016 (Contd..14)
  • Products under Development by Companies, H1 2016 (Contd..15)
  • Products under Development by Companies, H1 2016 (Contd..16)
  • Products under Development by Companies, H1 2016 (Contd..17)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Asthma - Pipeline by 4D Pharma Plc, H1 2016
  • Asthma - Pipeline by AB Science SA, H1 2016
  • Asthma - Pipeline by Abeome Corporation, H1 2016
  • Asthma - Pipeline by Accolade Pharmaceuticals, LLC, H1 2016
  • Asthma - Pipeline by Acorda Therapeutics, Inc., H1 2016
  • Asthma - Pipeline by Adamis Pharmaceuticals Corporation, H1 2016
  • Asthma - Pipeline by Advinus Therapeutics Ltd., H1 2016
  • Asthma - Pipeline by Afferent Pharmaceuticals, Inc., H1 2016
  • Asthma - Pipeline by ALK-Abello A/S, H1 2016
  • Asthma - Pipeline by Allergopharma GmbH & Co. KG, H1 2016
  • Asthma - Pipeline by Almirall, S.A., H1 2016
  • Asthma - Pipeline by Amakem NV, H1 2016
  • Asthma - Pipeline by Amgen Inc., H1 2016
  • Asthma - Pipeline by AnaptysBio, Inc., H1 2016
  • Asthma - Pipeline by Antisense Therapeutics Limited, H1 2016
  • Asthma - Pipeline by Aquinox Pharmaceuticals Inc., H1 2016
  • Asthma - Pipeline by ARA Healthcare Pvt. Ltd., H1 2016
  • Asthma - Pipeline by Ario Pharma Ltd, H1 2016
  • Asthma - Pipeline by ASIT biotech s.a., H1 2016
  • Asthma - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2016
  • Asthma - Pipeline by Astellas Pharma Inc., H1 2016
  • Asthma - Pipeline by AstraZeneca Plc, H1 2016
  • Asthma - Pipeline by Asubio Pharma Co., Ltd., H1 2016
  • Asthma - Pipeline by Aurigene Discovery Technologies Limited, H1 2016
  • Asthma - Pipeline by Axikin Pharmaceuticals, Inc., H1 2016
  • Asthma - Pipeline by Baxalta Incorporated, H1 2016
  • Asthma - Pipeline by Bioncotech Therapeutics S.L., H1 2016
  • Asthma - Pipeline by Biotec Pharmacon ASA, H1 2016
  • Asthma - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Asthma - Pipeline by Caladrius Biosciences, Inc. , H1 2016
  • Asthma - Pipeline by CalciMedica, Inc., H1 2016
  • Asthma - Pipeline by Carolus Therapeutics, Inc., H1 2016
  • Asthma - Pipeline by Cellceutix Corporation, H1 2016
  • Asthma - Pipeline by Cellular Biomedicine Group, Inc., H1 2016
  • Asthma - Pipeline by Celon Pharma Sp. z o.o., H1 2016
  • Asthma - Pipeline by Chiesi Farmaceutici SpA, H1 2016
  • Asthma - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016
  • Asthma - Pipeline by Circassia Pharmaceuticals Plc, H1 2016
  • Asthma - Pipeline by Cognosci, Inc., H1 2016
  • Asthma - Pipeline by CSL Limited, H1 2016
  • Asthma - Pipeline by Cumberland Pharmaceuticals, Inc., H1 2016
  • Asthma - Pipeline by Cytokinetics, Inc., H1 2016
  • Asthma - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Asthma - Pipeline by Dynavax Technologies Corporation, H1 2016
  • Asthma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Asthma - Pipeline by Five Prime Therapeutics, Inc., H1 2016
  • Asthma - Pipeline by Foresee Pharmaceuticals, LLC, H1 2016
  • Asthma - Pipeline by Fountain Biopharma Inc., H1 2016
  • Asthma - Pipeline by Genentech, Inc., H1 2016
  • Asthma - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Asthma - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2016
  • Asthma - Pipeline by GliaCure Inc., H1 2016
  • Asthma - Pipeline by Griffin Discoveries BV, H1 2016
  • Asthma - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016
  • Asthma - Pipeline by Hydra Biosciences, Inc., H1 2016
  • Asthma - Pipeline by iCeutica, Inc., H1 2016
  • Asthma - Pipeline by iCo Therapeutics Inc., H1 2016
  • Asthma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016
  • Asthma - Pipeline by INOXIA Lifesciences GmbH, H1 2016
  • Asthma - Pipeline by Invion Limited, H1 2016
  • Asthma - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2016
  • Asthma - Pipeline by Johnson & Johnson, H1 2016
  • Asthma - Pipeline by Kineta, Inc., H1 2016
  • Asthma - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2016
  • Asthma - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016
  • Asthma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016
  • Asthma - Pipeline by Laboratoires Pierre Fabre SA, H1 2016
  • Asthma - Pipeline by Lead Discovery Center GmbH, H1 2016
  • Asthma - Pipeline by LegoChem Biosciences, Inc, H1 2016
  • Asthma - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016
  • Asthma - Pipeline by Lpath, Inc., H1 2016
  • Asthma - Pipeline by Marinomed Biotechnologie GmbH, H1 2016
  • Asthma - Pipeline by MedImmune, LLC, H1 2016
  • Asthma - Pipeline by Merck & Co., Inc., H1 2016
  • Asthma - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016
  • Asthma - Pipeline by Mycenax Biotech Inc., H1 2016
  • Asthma - Pipeline by NAL Pharmaceuticals Ltd., H1 2016
  • Asthma - Pipeline by NeoPharm Co., Ltd., H1 2016
  • Asthma - Pipeline by Nostrum Pharmaceuticals, LLC, H1 2016
  • Asthma - Pipeline by Novartis AG, H1 2016
  • Asthma - Pipeline by Omeros Corporation, H1 2016
  • Asthma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
  • Asthma - Pipeline by OPKO Health, Inc., H1 2016
  • Asthma - Pipeline by Orbis Biosciences, Inc., H1 2016
  • Asthma - Pipeline by Orion Oyj, H1 2016
  • Asthma - Pipeline by Oxagen Limited, H1 2016
  • Asthma - Pipeline by Palatin Technologies, Inc., H1 2016
  • Asthma - Pipeline by Panacea Biotec Limited, H1 2016
  • Asthma - Pipeline by Panmira Pharmaceuticals, LLC., H1 2016
  • Asthma - Pipeline by Peptinnovate Limited, H1 2016
  • Asthma - Pipeline by PharmaLundensis AB, H1 2016
  • Asthma - Pipeline by Pharmaxis Limited, H1 2016
  • Asthma - Pipeline by Plexxikon Inc., H1 2016
  • Asthma - Pipeline by Polyphor Ltd., H1 2016
  • Asthma - Pipeline by Promedior, Inc., H1 2016
  • Asthma - Pipeline by Protectimmun GmbH, H1 2016
  • Asthma - Pipeline by Pulmagen Therapeutics LLP, H1 2016
  • Asthma - Pipeline by Re-Pharm Limited, H1 2016
  • Asthma - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016
  • Asthma - Pipeline by Respiratorius AB, H1 2016
  • Asthma - Pipeline by ReveraGen BioPharma, Inc., H1 2016
  • Asthma - Pipeline by Rhizen Pharmaceuticals S.A., H1 2016
  • Asthma - Pipeline by Saje Pharma, LLC, H1 2016
  • Asthma - Pipeline by SkyePharma Plc, H1 2016
  • Asthma - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2016
  • Asthma - Pipeline by Stallergenes SAS, H1 2016
  • Asthma - Pipeline by sterna biologicals Gmbh & Co KG, H1 2016
  • Asthma - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016
  • Asthma - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016
  • Asthma - Pipeline by Sunovion Pharmaceuticals Inc., H1 2016
  • Asthma - Pipeline by Swecure AB, H1 2016
  • Asthma - Pipeline by Synovo GmbH, H1 2016
  • Asthma - Pipeline by Syntrix Biosystems, Inc., H1 2016
  • Asthma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Asthma - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016
  • Asthma - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016
  • Asthma - Pipeline by Therabron Therapeutics, Inc., H1 2016
  • Asthma - Pipeline by Theraclone Sciences, Inc., H1 2016
  • Asthma - Pipeline by Theravance Biopharma, Inc., H1 2016
  • Asthma - Pipeline by Tolerys SA, H1 2016
  • Asthma - Pipeline by UCB S.A., H1 2016
  • Asthma - Pipeline by United BioPharma, Inc., H1 2016
  • Asthma - Pipeline by Vectura Group Plc, H1 2016
  • Asthma - Pipeline by Verona Pharma Plc, H1 2016
  • Asthma - Pipeline by WhanIn Pharmaceutical Co., Ltd., H1 2016
  • Asthma - Pipeline by Xencor, Inc., H1 2016
  • Asthma - Pipeline by Yungjin Pharm. Co., Ltd., H1 2016
  • Asthma - Pipeline by Zambon Company S.p.A., H1 2016
  • Asthma - Pipeline by Ziarco Pharma Ltd, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Asthma Therapeutics - Recent Pipeline Updates, H1 2016
  • Asthma - Dormant Projects, H1 2016
  • Asthma - Dormant Projects (Contd..1), H1 2016
  • Asthma - Dormant Projects (Contd..2), H1 2016
  • Asthma - Dormant Projects (Contd..3), H1 2016
  • Asthma - Dormant Projects (Contd..4), H1 2016
  • Asthma - Dormant Projects (Contd..5), H1 2016
  • Asthma - Dormant Projects (Contd..6), H1 2016
  • Asthma - Dormant Projects (Contd..7), H1 2016
  • Asthma - Dormant Projects (Contd..8), H1 2016
  • Asthma - Dormant Projects (Contd..9), H1 2016
  • Asthma - Dormant Projects (Contd..10), H1 2016
  • Asthma - Dormant Projects (Contd..11), H1 2016
  • Asthma - Dormant Projects (Contd..12), H1 2016
  • Asthma - Dormant Projects (Contd..13), H1 2016
  • Asthma - Dormant Projects (Contd..14), H1 2016
  • Asthma - Dormant Projects (Contd..15), H1 2016
  • Asthma - Dormant Projects (Contd..16), H1 2016
  • Asthma - Dormant Projects (Contd..17), H1 2016
  • Asthma - Dormant Projects (Contd..18), H1 2016
  • Asthma - Dormant Projects (Contd..19), H1 2016
  • Asthma - Dormant Projects (Contd..20), H1 2016
  • Asthma - Dormant Projects (Contd..21), H1 2016
  • Asthma - Dormant Projects (Contd..22), H1 2016
  • Asthma - Dormant Projects (Contd..23), H1 2016
  • Asthma - Dormant Projects (Contd..24), H1 2016
  • Asthma - Dormant Projects (Contd..25), H1 2016
  • Asthma - Dormant Projects (Contd..26), H1 2016
  • Asthma - Dormant Projects (Contd..27), H1 2016
  • Asthma - Dormant Projects (Contd..28), H1 2016
  • Asthma - Dormant Projects (Contd..29), H1 2016
  • Asthma - Dormant Projects (Contd..30), H1 2016
  • Asthma - Dormant Projects (Contd..31), H1 2016
  • Asthma - Dormant Projects (Contd..32), H1 2016
  • Asthma - Dormant Projects (Contd..33), H1 2016
  • Asthma - Discontinued Products, H1 2016
  • Asthma - Discontinued Products (Contd..1), H1 2016
  • Asthma - Discontinued Products (Contd..2), H1 2016
  • Asthma - Discontinued Products (Contd..3), H1 2016
  • Asthma - Discontinued Products (Contd..4), H1 2016
  • Asthma - Discontinued Products (Contd..5), H1 2016
  • Asthma - Discontinued Products (Contd..6), H1 2016
  • Asthma - Discontinued Products (Contd..7), H1 2016
  • Asthma - Discontinued Products (Contd..8), H1 2016

List of Figures

  • Number of Products under Development for Asthma, H1 2016
  • Number of Products under Development for Asthma - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top